期刊
VACCINE
卷 39, 期 50, 页码 7277-7285出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2021.06.049
关键词
BCG; MTBVAC; Protection; Newborns; Trained immunity
资金
- Spanish research projects [RTC-2017-6379-1]
- European Commission [643381]
- CDRMP of the United States government
- European & Developing Countries Clinical Trials Partnership EDCTP2 [RIA-2016-V-1637MTBVACN2]
- EDCTP [RIA2019S-2652]
- INH
BCG has been a key inspiration for the development of numerous new TB vaccine candidates, with MTBVAC as one of them. MTBVAC, based on a live-attenuated Mycobacterium tuberculosis clinical isolate, is set to begin Phase 3 efficacy trials in TB-endemic countries. Recent studies suggest that MTBVAC can induce trained immunity and confer non-specific heterologous protection similar to BCG, showing promising potential for long-term TB eradication programs.
At its 100th birthday of its first administration to a newborn, BCG has been (and continues being) an inspiration for the construction and development of hundreds of new TB vaccine candidates in the last two and a half decades. Today, 14 candidates are in clinical development inside the global TB vaccine pipeline. MTBVAC is one of these candidates. Based on a live-attenuated Mycobacterium tuberculosis clinical isolate, MTBVAC's 25 years of vaccine discovery, construction and characterisation have followed Pasteur principles, and in the process, BCG has served as a reference gold standard for establishing the safety and protective efficacy of new TB vaccine candidates. MTBVAC, which contains the antigen repertoire of M. tuberculosis, is now poised to initiate Phase 3 efficacy trials in newborns in TB-endemic countries. BCG's efficacy extends beyond that against TB, shown to confer heterologous non-specific immunity to other diseases and reduce all-cause mortality in the first months of life. Today, WHO recognises the importance that any new TB vaccine designed for administration at birth, should show similar nonspecific benefits as BCG via mechanisms of trained immunity and/or cross-reactivity of adaptive immune responses to other pathogens. Key recent studies provide strong support for MTBVAC's ability of inducing trained immunity and conferring non-specific heterologous protection similar to BCG. Research on alternative delivery routes of MTBVAC, such as a clinically feasible aerosol route, could facilitate vaccine administration for long-term TB eradication programmes in the future. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据